Date: 2016-07-26
Type of information: Product acquisition
Compound: lomibuvir (VX-222) and merimepodib (VX-497)
Company: Trek Therapeutics (USA - MA) Vertex Pharmaceuticals (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: product acquisition
Action mechanism:
- direct-acting antiviral agent/NS5B polymerase inhibitor/inosine monosphosphate dehydrogenase inhibitor. Lomibuvir is an oral non-nucleoside inhibitor of the HCV NS5B polymerase with potent activity against genotype 1a and 1b. Lomibuvir has completed Phase 2b clinical studies in HCV patients.
- Merimepodib is an oral inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH inhibition leads to a reduction in intracellular guanosine triphosphate (GTP), a molecule required for DNA and RNA synthesis and represents an attractive strategy for treating infectious diseases. Merimipodib has completed Phase 2b clinical studies in HCV patients.
Disease:
Details:
- • On July 26, 2016, Trek Therapeutics announced that it acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals .
- Vertex will be eligible to receive milestones and royalties based on successful development and commercialization of lomibuvir and merimepodib. Other terms were not disclosed.
Financial terms:
Latest news:
Is general: Yes
